Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up – Here’s What Happened

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) gapped up before the market opened on Tuesday . The stock had previously closed at $7.23, but opened at $7.45. Aligos Therapeutics shares last traded at $7.44, with a volume of 861 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Friday, September 20th.

Aligos Therapeutics Price Performance

The firm’s 50 day moving average is $11.57 and its 200 day moving average is $14.47. The company has a market capitalization of $569.42 million, a PE ratio of -5.65 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The firm had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter in the previous year, the firm posted ($10.75) EPS. As a group, analysts predict that Aligos Therapeutics, Inc. will post -8.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC increased its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after buying an additional 98,628 shares during the period. Opaleye Management Inc. boosted its holdings in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after acquiring an additional 333,000 shares in the last quarter. Finally, Armistice Capital LLC increased its position in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the period. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).